Walleye Capital
RVNC

Walleye Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Walleye Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-699,621
Closed -$3.63M – 5776
2024
Q3 		$3.63M Buy
699,621
+88,829
+15% +$441K 0.01% 1418
2024
Q2 		$1.57M Sell
610,792
-11,334
-2% -$38.7K ﹤0.01% 2346
2024
Q1 		$3.06M Sell
622,126
-305,688
-33% -$1.81M 0.01% 1675
2023
Q4 		$8.16M Buy
927,814
+622,022
+203% +$5.1M 0.02% 794
2023
Q3 		$3.51M Buy
305,792
+192,004
+169% +$3.69M 0.01% 1298
2023
Q2 		$2.88M Sell
113,788
-166,574
-59% -$5.19M 0.01% 1074
2023
Q1 		$9.03M Sell
280,362
-228,333
-45% -$7.12M 0.14% 165
2022
Q4 		$9.39M Sell
508,695
-14,350
-3% -$328K 0.17% 134
2022
Q3 		$14.1M Buy
523,045
+58,075
+12% +$1.18M 0.27% 58
2022
Q2 		$6.43M Sell
464,970
-40,731
-8% -$627K 0.18% 131
2022
Q1 		$9.86M Buy
505,701
+148,464
+42% +$2.25M 0.26% 79
2021
Q4 		$5.83M Buy
357,237
+302,760
+556% +$5.05M 0.18% 119
2021
Q3 		$1.52M Sell
54,477
-52,382
-49% -$1.49M 0.04% 298
2021
Q2 		$3.17M Buy
106,859
+36,610
+52% +$1.06M 0.11% 156
2021
Q1 		$1.96M Sell
70,249
-1,116
-2% -$30.9K 0.11% 151
2020
Q4 		$2.02M Buy
+71,365
New +$1.85M 0.14% 123
2018
Q3 		$438K Buy
+17,644
New +$480K 0.2% 142

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Walleye Capital's RVNC Position: Q4 2024 in Review

Walleye Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 699,621 shares — an estimated $3.63M sold.

Walleye Capital first reported a position in RVNC in Q3 2018 and held it in 17 quarters. The position peaked at $14.1M in Q3 2022. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Walleye Capital reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 699,621 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $3.63M.
  • Walleye Capital first reported a position in Revance Therapeutics, Inc. in Q3 2018 and held it in 17 quarters.
  • Walleye Capital's Revance Therapeutics, Inc. position peaked at $14.1M in Q3 2022.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.